Bone Biologics (BBLG) Shares Outstanding (Diluted Average) (2016 - 2025)
Bone Biologics (BBLG) reported Shares Outstanding (Diluted Average) of $1.2 million for Q4 2025, up 364.45% year-over-year from $252960.0 in Q4 2024, and down 34.55% quarter-over-quarter from $1.8 million in Q3 2025.
Bone Biologics (BBLG) Shares Outstanding (Diluted Average) (2016 - 2025) Analysis & Trends
Bone Biologics (BBLG) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $1.2 million in Q4 2025.
- Shares Outstanding (Diluted Average) for Q4 2025 came in at $1.2 million, up 364.45% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.2 million (up 364.45% YoY), and the FY2025 annual result was $1.2 million, up 364.45% from the prior year.
- Shares Outstanding (Diluted Average) retreated to $1.2 million in Q4 2025 per BBLG's latest filing, from $1.8 million in the prior quarter.
- Over five years, Shares Outstanding (Diluted Average) peaked at $3.2 million in Q1 2025 and troughed at $47658.0 in Q4 2022.
- A 4-year average of $644992.9 and a median of $339308.0 in 2023 frame the typical range for Shares Outstanding (Diluted Average).
- On a YoY basis, Shares Outstanding (Diluted Average) climbed as much as 883.36% in 2024 and fell as far as 55.05% in 2024.
- A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $47658.0 in 2022, then soared by 452.14% to $263137.0 in 2023, then slipped by 3.87% to $252960.0 in 2024, then soared by 364.45% to $1.2 million in 2025.
- Business Quant data shows BBLG's Shares Outstanding (Diluted Average) at $1.2 million in Q4 2025, $1.8 million in Q3 2025, and $557787.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 92.44 Mn |
| 10 | Bone Biologics | 1.47 Mn | 1.47 Mn | - | 1.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.17 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 557,787.00 |
| Mar 31, 2025 | 3.18 Mn |
| Dec 31, 2024 | 252,960.00 |
| Sep 30, 2024 | 292,321.00 |
| Jun 30, 2024 | 152,533.00 |
| Mar 31, 2024 | 660,928.00 |
| Dec 31, 2023 | 263,137.00 |
| Sep 30, 2023 | 197,855.00 |
| Jun 30, 2023 | 339,308.00 |
| Mar 31, 2023 | 67,211.00 |
| Dec 31, 2022 | 47,658.00 |
| Sep 30, 2022 | 345,019.00 |
| Jun 30, 2022 | 345,019.00 |
| Jun 30, 2018 | 4.38 Mn |
| Jun 30, 2017 | 4.07 Mn |
| Jun 30, 2016 | 38.15 Mn |